Get the Stockscreener App
24.53
4.65%
1.09
Pre-market:
24.44
-0.09
-0.37%
Beam Therapeutics Inc stock is traded at $24.53, with a volume of 790.79K.
It is up +4.65% in the last 24 hours and down -15.44% over the past month.
Beam Therapeutics Inc is a biotechnology company engaged in creating genetic medicines based on its base editing technology. This technology enables a new class of genetic medicines that targets a single base in the genome without making a double-stranded break in the DNA. The company's portfolio comprises Gene Correction, Gene Modification, Gene Activation, Gene Silencing, and Multiplex Editing. The company's pipeline programs consist of BEAM-101, ESCAPE, BEAM-302, BEAM-301, and BEAM-201.
See More
Previous Close:
$23.44
Open:
$23.75
24h Volume:
790.79K
Relative Volume:
0.68
Market Cap:
$2.03B
Revenue:
$352.57M
Net Income/Loss:
$-143.01M
P/E Ratio:
-13.55
EPS:
-1.81
Net Cash Flow:
$-153.40M
1W Performance:
+5.28%
1M Performance:
-15.44%
6M Performance:
-5.44%
1Y Performance:
+3.55%
1-Day Range:
$23.54
$24.60
1-Week Range:
$22.50
$25.07
52-Week Range:
$20.84
$49.50
Beam Therapeutics Inc Stock (BEAM) Company Profile
Name
Beam Therapeutics Inc
Sector
Industry
Phone
857-327-8775
Address
26 LANDSDOWNE STREET, CAMBRIDGE, MA
Compare BEAM with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
BEAM
Beam Therapeutics Inc
|
24.53 | 2.03B | 352.57M | -143.01M | -153.40M | -1.81 |
|
VRTX
Vertex Pharmaceuticals Inc
|
427.89 | 110.19B | 10.63B | -479.80M | -1.35B | -1.99 |
|
REGN
Regeneron Pharmaceuticals Inc
|
687.80 | 75.58B | 13.85B | 4.65B | 3.32B | 40.41 |
|
ARGX
Argen X Se Adr
|
647.39 | 38.71B | 1.86B | -40.29M | -1.28B | -0.85 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
264.99 | 34.18B | 2.09B | -332.26M | 16.06M | -2.62 |
|
BNTX
Biontech Se Adr
|
117.25 | 28.11B | 3.30B | -501.07M | 1.03B | -2.1146 |
Beam Therapeutics Inc Stock (BEAM) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Nov-06-24 | Upgrade | Leerink Partners | Market Perform → Outperform |
| Oct-16-24 | Initiated | Scotiabank | Sector Outperform |
| Jul-23-24 | Initiated | H.C. Wainwright | Buy |
| Jan-29-24 | Upgrade | JP Morgan | Neutral → Overweight |
| Dec-15-23 | Downgrade | BofA Securities | Buy → Neutral |
| Dec-08-23 | Downgrade | Jefferies | Buy → Hold |
| Oct-20-23 | Downgrade | Cantor Fitzgerald | Overweight → Neutral |
| Oct-20-23 | Downgrade | Leerink Partners | Outperform → Market Perform |
| Mar-21-23 | Initiated | Bernstein | Mkt Perform |
| Feb-01-23 | Initiated | Cantor Fitzgerald | Overweight |
| Dec-20-22 | Upgrade | BMO Capital Markets | Market Perform → Outperform |
| Dec-13-22 | Initiated | Citigroup | Buy |
| Jun-17-22 | Initiated | BMO Capital Markets | Market Perform |
| Apr-28-22 | Initiated | Credit Suisse | Neutral |
| Jan-05-22 | Initiated | Guggenheim | Buy |
| Oct-19-21 | Initiated | SVB Leerink | Outperform |
| Sep-24-21 | Resumed | Stifel | Buy |
| Sep-10-21 | Initiated | BofA Securities | Buy |
| May-11-21 | Initiated | Redburn | Buy |
| May-04-21 | Initiated | RBC Capital Mkts | Sector Perform |
| Mar-01-21 | Downgrade | Barclays | Overweight → Equal Weight |
| Feb-16-21 | Initiated | Wells Fargo | Overweight |
| Jan-29-21 | Downgrade | JP Morgan | Overweight → Neutral |
| Jan-06-21 | Initiated | Stifel | Hold |
| Aug-05-20 | Initiated | William Blair | Outperform |
| Mar-02-20 | Initiated | Barclays | Overweight |
| Mar-02-20 | Initiated | JP Morgan | Overweight |
| Mar-02-20 | Initiated | Jefferies | Buy |
| Mar-02-20 | Initiated | Wedbush | Outperform |
View All
Beam Therapeutics Inc Stock (BEAM) Latest News
Beam Therapeutics: Too Expensive For Me, But Watch For Important Catalysts - Seeking Alpha
50,285 Shares in Beam Therapeutics Inc. (NASDAQ:BEAM) Bought by Avanza Fonder AB - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Consensus Rating of "Moderate Buy" by Brokerages - MarketBeat
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones - MSN
Beam Therapeutics' SWOT analysis: gene editing pioneer's stock faces crucial clinical milestones By Investing.com - Investing.com South Africa
Beam Therapeutics (NASDAQ:BEAM) Shares Down 8%Should You Sell? - MarketBeat
Beam Therapeutics’ (BEAM) “Outperform” Rating Reaffirmed at Wedbush - Defense World
Beam Therapeutics (NASDAQ:BEAM) Given Outperform Rating at Wedbush - MarketBeat
Beam Therapeutics (NASDAQ:BEAM) Trading Down 8%Time to Sell? - MarketBeat
Is Beam Therapeutics (BEAM) Stock a Solid Choice Right Now? - MSN
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates By Investing.com - Investing.com South Africa
Beam Therapeutics advances gene editing trials, eyes mid-2025 updates - Investing.com India
Beam Therapeutics Announces Progress in Hematology and - GlobeNewswire
Beam Therapeutics Advances Sickle Cell Treatment: 13 Patients Dosed, $850M Cash Position Powers 2025 Pipeline - StockTitan
Catherine Wood's Strategic Reduction in Beam Therapeutics Inc - GuruFocus.com
JPMorgan Chase & Co. Sells 144,127 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
2 Stocks for Bulls This Year: Beam Therapeutics, Bloom Energy - Schaeffers Research
Beam upgraded by Bernstein ahead of AATD data - MSN
Breakthrough Gene Editing Technique Offers Hope for Stargardt Disease Patients - Yahoo Finance
Beam Therapeutics (NASDAQ:BEAM) Trading Up 6.7%Here's What Happened - MarketBeat
Beam upgraded by Bernstein ahead of AATD data (BEAM:NASDAQ) - Seeking Alpha
Beam Therapeutics chief legal officer sells $30,627 in stock By Investing.com - Investing.com Australia
Beam Therapeutics Inc. (NASDAQ:BEAM) Insider Sells $30,627.88 in Stock - MarketBeat
Beam Therapeutics chief legal officer sells $30,627 in stock - Investing.com India
Beam Therapeutics SVP Bethany J Cavanagh sells $27,567 in stock By Investing.com - Investing.com Canada
(BEAM) Technical Pivots with Risk Controls - Stock Traders Daily
Top 5 CRISPR Companies To Invest In (January 2025) - Securities.io
Why Is Beam Therapeutics Inc. (BEAM) Among the Top CRISPR Stocks to Invest In? - Insider Monkey
Beam Therapeutics Breaks Below 200-Day Moving AverageNotable for BEAM - Nasdaq
Top 11 CRISPR Stocks to Invest In - Insider Monkey
Beam Therapeutics Inc. (BEAM): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance
10 Best Gene Therapy Stocks to Buy Right Now - Insider Monkey
Beam Therapeutics (NASDAQ:BEAM) Trading Down 2.6%Time to Sell? - MarketBeat
Beam Therapeutics Inc. (NASDAQ:BEAM) Given Average Rating of "Moderate Buy" by Brokerages - MarketBeat
Geode Capital Management LLC Has $44.30 Million Position in Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
(BEAM) Long Term Investment Analysis - Stock Traders Daily
5 Biotech Breakthrough Stocks to Watch in 2025 - Yahoo Finance
Here's Why We're Not At All Concerned With Beam Therapeutics' (NASDAQ:BEAM) Cash Burn Situation - Simply Wall St
Comprehensive Market Analysis of Latest Published 9 Rare Genetic Disorders Reports | DelveInsight - GlobeNewswire Inc.
Beam Therapeutics (BEAM) Stock Dips Amid Biotech Sector Decline - GuruFocus.com
Beam Therapeutics to Present at the 43rd Annual J.P. Morgan Healthcare Conference - The Manila Times
Beam Therapeutics CEO to Present at J.P. Morgan Healthcare Conference: Precision Gene Editing Spotlight - StockTitan
State Street Corp Purchases 437,402 Shares of Beam Therapeutics Inc. (NASDAQ:BEAM) - MarketBeat
Beam Therapeutics Inc Stock (BEAM) Financials Data
Revenue
Net Income
Cash Flow
EPS
4.81%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):